Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis

BMC Musculoskeletal Disorders

Volumn 14, Issue , 2013, Pages

  Bae, Sang Cheol ^a   Gun, Suk Chyn ^b   Mok, Chi Chiu ^c   Khandker, Rezaul ^d   Nab, Henk W ^d   Koenig, Andrew S ^d   Vlahos, Bonnie ^d   Pedersen, Ron ^d   Singh, Amitabh ^d  

^a Hanyang Institute of Bioscience and Biotechnology   (South Korea)

^b Seremban Hospital   (Malaysia)

^c TUEN MUN HOSPITAL   (Hong Kong)

^d PFIZER INC   (United States)

Author keywords

Asia Pacific; Etanercept; Health outcomes assessments; Patient reported outcomes; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; ASIAN; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PARALLEL DESIGN; PHASE 4 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SHORT FORM 36; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIA; ASIAN CONTINENTAL ANCESTRY GROUP; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; EMOTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MENTAL HEALTH; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871976126     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-14-13     Document Type: Article

References (27)

1. Rheumatology outcomes: the patient's perspective. Carr A, Hewlett S, Hughes R, Mitchell H, Ryan S, Carr M, J Rheumatol 2003 30 880 883 12672221 (Pubitemid 36402793)
2. Patient perspective in outcome assessments-perceptions or something more? Kvien TK, Heiberg T, J Rheumatol 2003 30 873 876 12672219 (Pubitemid 36402791)
3. Rheumatoid arthritis. Lee DM, Weinblatt ME, Lancet 2001 358 903 911 10.1016/S0140-6736(01)06075-5 11567728 (Pubitemid 32900579)
4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Ann Rheum Dis 2010 69 964 975 10.1136/ard.2009.126532 20444750
5. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Arthritis Rheum 2008 59 762 784 10.1002/art.23721 18512708 (Pubitemid 351847559)
6. Treating rheumatoid arthritis to target: recommendations of an international task force. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, Ann Rheum Dis 2010 69 631 637 10.1136/ard.2009.123919 20215140
7. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Lancet 2008 372 375 382 10.1016/S0140-6736(08)61000-4 18635256
8. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Aletaha D, Smolen J, Ward MM, Arthritis Rheum 2006 54 2784 2792 10.1002/art.22052 16947781 (Pubitemid 44497757)
9. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr, Arthritis Rheum 2000 43 1478 1487 10.1002/1529-0131(200007)43:7<1478::AID-ANR10>3.0. CO;2-M 10902749 (Pubitemid 30452465)
10. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, N Engl J Med 2000 343 1586 1593 10.1056/NEJM200011303432201 11096165 (Pubitemid 32162981)
11. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Arthritis Rheum 2002 46 1443 1450 10.1002/art.10308 12115173 (Pubitemid 34620189)
12. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Ann Intern Med 1999 130 478 486 10075615 (Pubitemid 29135800)
13. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, Ann Rheum Dis 2010 69 222 225 10.1136/ard.2008.102509 19293160
14. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, Ann Rheum Dis 2006 65 328 334 10.1136/ard.2005.035709 16079172 (Pubitemid 43268221)
15. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, Int J Rheum Dis 2012 15 188 196 10.1111/j.1756-185X.2011.01680.x 22462423
16. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 (Pubitemid 18091653)
17. The hospital anxiety and depression scale. Zigmond AS, Snaith RP, Acta Psychiatr Scand 1983 67 361 370 10.1111/j.1600-0447.1983.tb09716.x 6880820 (Pubitemid 13098606)
18. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J, J Rheumatol 2005 32 811 819 15868614 (Pubitemid 40676488)
19. The validity and reproducibility of a work productivity and activity impairment instrument. Reilly MC, Zbrozek AS, Dukes EM, Pharmacoeconomics 1993 4 353 365 10.2165/00019053-199304050-00006 10146874
20. Self-reported fatigue in rheumatoid arthritis. A pilot study. Tack BB, Arthritis Care Res 1990 3 154 157 2285754
21. Comparison of self-reported fatigue in rheumatoid arthritis and controls. Belza BL, J Rheumatol 1995 22 639 643 7791155
22. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Ann Rheum Dis 2008 67 1360 1364 10.1136/ard.2008.091454 18791055
23. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S, J Clin Epidemiol 2008 61 705 713 10.1016/j.jclinepi.2007.08.016 18359189
24. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Strand V, Singh JA, Am J Manag Care 2007 13 Suppl 9 237 S251 18095787
25. Longterm treatment benefits are best reflected by patient reported outcomes. Strand CV, Crawford B, J Rheumatol 2007 34 2317 2319 18061963 (Pubitemid 350230649)
26. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC, Rheumatology (Oxford) 2009 48 1152 1154 10.1093/rheumatology/kep170
27. Agency for Healthcare Research and Quality, Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults. Executive summary Agency for Healthcare Research and Quality 2007 5-5-2010. http://www.effectivehealthcare.ahrq.gov/ehc/products/14/70/ RheumArthritisExecSum.pdf